Literature DB >> 26528764

Prenatal diagnosis of Bartter syndrome: amniotic fluid aldosterone.

Myriam L Rachid1, Sophie Dreux1, Gauthier Pean de Ponfilly1, Rosa Vargas-Poussou2, Isabelle Czerkiewicz1, Didier Chevenne1, Jean-François Oury3, Georges Deschênes4, Françoise Muller1,5.   

Abstract

OBJECTIVE: Bartter syndrome is a severe inherited tubulopathy characterized by postnatal salt wasting, severe polyuria, dehydration, failure to thrive and secondary hyperaldosteronism. Prenatally, the disease is usually discovered following the onset of severe polyhydramnios in the second trimester. We studied amniotic fluid aldosterone concentration in Bartter syndrome and in controls.
METHODS: Amniotic fluid aldosterone was assayed by radioimmunoassay. We undertook a retrospective case-control study based on 36 cases of prenatally suspected and postnatally confirmed Bartter syndrome (22 with identified mutations): and 72 gestational age matched controls presenting with polyhydramnios and 72 without polyhydramnios. Amniotic fluid aldosterone was compared between the three groups.
RESULTS: The median amniotic fluid aldosterone concentration in the Bartter syndrome group (90 pg/mL) was not different from that in the controls with polyhydramnios (90 pg/mL, P = 0.33) or without polyhydramnios (87 pg/mL, P = 0.41).
CONCLUSION: Amniotic fluid aldosterone assay cannot be used for prenatal diagnosis of Bartter syndrome.
© 2015 John Wiley & Sons, Ltd. © 2015 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26528764     DOI: 10.1002/pd.4717

Source DB:  PubMed          Journal:  Prenat Diagn        ISSN: 0197-3851            Impact factor:   3.050


  2 in total

Review 1.  Bartter syndrome: causes, diagnosis, and treatment.

Authors:  Tamara da Silva Cunha; Ita Pfeferman Heilberg
Journal:  Int J Nephrol Renovasc Dis       Date:  2018-11-09

2.  A Rare Cause of Refractory Severe Polyhydramnios: Antenatal Bartter Syndrome.

Authors:  Gina Nam; Angela Cho; Mi-Hye Park
Journal:  Medicina (Kaunas)       Date:  2021-03-16       Impact factor: 2.430

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.